Nexentis Technologies Inc.
As of Oct 22, 2026, Nexentis Technologies is in Stage 4, the downtrend phase, now in week 14 (since Jul 20, 2026). It closed at $0.57, 98.0% below its 52-week high and below its 200-day average, which is falling.
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NXTS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NXTS among Agricultural Inputs13th of 13 by relative strength
All 13 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | UAN | Stage 2 · wk 10 | 88 | −2.0% |
| 2 | CF | Stage 3 · wk 2 | 84 | −1.7% |
| 3 | CTVA | Stage 2 · wk 1 | 82 | +6.6% |
| 4 | NTR | Stage 2 · wk 8 | 74 | −7.3% |
| 5 | SMG | Stage 4 · wk 5 | 64 | +12.0% |
| 6 | IPI | Stage 4 · wk 1 | 64 | −16.2% |
| 7 | ICL | Stage 4 · wk 1 | 38 | −11.1% |
| 8 | MOS | Stage 4 · wk 2 | 29 | −29.1% |
| …13 | NXTS | Stage 4 · wk 14 | 4 | −61.0% |
Nexentis Technologies: quick answers
What stage is Nexentis Technologies in?
As of Oct 22, 2026, Nexentis Technologies (NXTS) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 20, 2026 and is in week 14. What the four stages mean
Is Nexentis Technologies in an uptrend?
No. Nexentis Technologies is in a Stage 4 downtrend. It trades 87.3% below its 200-day average, which is falling.
How far is Nexentis Technologies from its 52-week high?
Nexentis Technologies closed at $0.57 on Oct 22, 2026, 98.0% below its 52-week high of $28.63. Its 52-week low is $0.54.
How has Nexentis Technologies performed over the past year?
As of Oct 22, 2026, Nexentis Technologies is down 98.0% over the past year and down 94.9% so far in 2026.
Which sector and industry is Nexentis Technologies in?
Nexentis Technologies is in the Agricultural Inputs industry, part of the Materials sector.
About this companyMaterials· Agricultural Inputs
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.